Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma

Takeaki Ishii, Kenichi Kouhashi, Hiroshi Ootsuka, Kunio Iura, Akira Maekawa, Yuichi Yamada, Hirofumi Bekki, Masato Yoshimoto, Hidetaka Yamamoto, Yukihide Iwamoto, Yoshinao Oda

研究成果: ジャーナルへの寄稿記事

1 引用 (Scopus)

抄録

It is important to distinguish between leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) in the retroperitoneum. The dedifferentiated component of DDLS shows an LMS-like morphology in some cases; thus, detailed evaluation is necessary to achieve an accurate diagnosis. Immunohistochemically, MDM2 and myogenic markers provide clues for the diagnoses. However, immunoreactivity for MDM2 and myogenic markers has not been well studied in retroperitoneal LMS and DDLS. Here, we compared the clinicopathological data of 20 retroperitoneal tumors initially diagnosed as LMS with that of 36 cases of retroperitoneal DDLS and conducted an immunohistochemical study. Four (20%) of the cases initially diagnosed as LMS were immunoreactive for MDM2. Fifteen cases (41.7%) of DDLS showed positive expression of two or more myogenic markers. The patients with LMS with MDM2 overexpression were older than the patients with LMS without MDM2 overexpression (P = 0.0328). LMS with MDM2 overexpression showed a worse prognosis than DDLS (P = 0.0408). No significant difference in prognosis was found between LMS without MDM2 overexpression and DDLS with myogenic differentiation. In conclusion, we recommend that systemic MDM2 expression analysis be performed in cases of retroperitoneal sarcoma. Overdependence on the expression of myogenic markers could lead to misdiagnosis in distinguishing LMS from DDLS.

元の言語英語
ページ(範囲)634-638
ページ数5
ジャーナルPathology Research and Practice
213
発行部数6
DOI
出版物ステータス出版済み - 6 1 2017

Fingerprint

Liposarcoma
Leiomyosarcoma
Retroperitoneal liposarcoma
Diagnostic Errors
Sarcoma

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Cell Biology

これを引用

Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma. / Ishii, Takeaki; Kouhashi, Kenichi; Ootsuka, Hiroshi; Iura, Kunio; Maekawa, Akira; Yamada, Yuichi; Bekki, Hirofumi; Yoshimoto, Masato; Yamamoto, Hidetaka; Iwamoto, Yukihide; Oda, Yoshinao.

:: Pathology Research and Practice, 巻 213, 番号 6, 01.06.2017, p. 634-638.

研究成果: ジャーナルへの寄稿記事

Ishii, Takeaki ; Kouhashi, Kenichi ; Ootsuka, Hiroshi ; Iura, Kunio ; Maekawa, Akira ; Yamada, Yuichi ; Bekki, Hirofumi ; Yoshimoto, Masato ; Yamamoto, Hidetaka ; Iwamoto, Yukihide ; Oda, Yoshinao. / Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma. :: Pathology Research and Practice. 2017 ; 巻 213, 番号 6. pp. 634-638.
@article{5b4cb1f73802478d8de2bb5db0bd4cec,
title = "Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma",
abstract = "It is important to distinguish between leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) in the retroperitoneum. The dedifferentiated component of DDLS shows an LMS-like morphology in some cases; thus, detailed evaluation is necessary to achieve an accurate diagnosis. Immunohistochemically, MDM2 and myogenic markers provide clues for the diagnoses. However, immunoreactivity for MDM2 and myogenic markers has not been well studied in retroperitoneal LMS and DDLS. Here, we compared the clinicopathological data of 20 retroperitoneal tumors initially diagnosed as LMS with that of 36 cases of retroperitoneal DDLS and conducted an immunohistochemical study. Four (20{\%}) of the cases initially diagnosed as LMS were immunoreactive for MDM2. Fifteen cases (41.7{\%}) of DDLS showed positive expression of two or more myogenic markers. The patients with LMS with MDM2 overexpression were older than the patients with LMS without MDM2 overexpression (P = 0.0328). LMS with MDM2 overexpression showed a worse prognosis than DDLS (P = 0.0408). No significant difference in prognosis was found between LMS without MDM2 overexpression and DDLS with myogenic differentiation. In conclusion, we recommend that systemic MDM2 expression analysis be performed in cases of retroperitoneal sarcoma. Overdependence on the expression of myogenic markers could lead to misdiagnosis in distinguishing LMS from DDLS.",
author = "Takeaki Ishii and Kenichi Kouhashi and Hiroshi Ootsuka and Kunio Iura and Akira Maekawa and Yuichi Yamada and Hirofumi Bekki and Masato Yoshimoto and Hidetaka Yamamoto and Yukihide Iwamoto and Yoshinao Oda",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.prp.2017.04.022",
language = "English",
volume = "213",
pages = "634--638",
journal = "Pathology Research and Practice",
issn = "0344-0338",
publisher = "Urban und Fischer Verlag GmbH und Co. KG",
number = "6",

}

TY - JOUR

T1 - Comparison between retroperitoneal leiomyosarcoma and dedifferentiated liposarcoma

AU - Ishii, Takeaki

AU - Kouhashi, Kenichi

AU - Ootsuka, Hiroshi

AU - Iura, Kunio

AU - Maekawa, Akira

AU - Yamada, Yuichi

AU - Bekki, Hirofumi

AU - Yoshimoto, Masato

AU - Yamamoto, Hidetaka

AU - Iwamoto, Yukihide

AU - Oda, Yoshinao

PY - 2017/6/1

Y1 - 2017/6/1

N2 - It is important to distinguish between leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) in the retroperitoneum. The dedifferentiated component of DDLS shows an LMS-like morphology in some cases; thus, detailed evaluation is necessary to achieve an accurate diagnosis. Immunohistochemically, MDM2 and myogenic markers provide clues for the diagnoses. However, immunoreactivity for MDM2 and myogenic markers has not been well studied in retroperitoneal LMS and DDLS. Here, we compared the clinicopathological data of 20 retroperitoneal tumors initially diagnosed as LMS with that of 36 cases of retroperitoneal DDLS and conducted an immunohistochemical study. Four (20%) of the cases initially diagnosed as LMS were immunoreactive for MDM2. Fifteen cases (41.7%) of DDLS showed positive expression of two or more myogenic markers. The patients with LMS with MDM2 overexpression were older than the patients with LMS without MDM2 overexpression (P = 0.0328). LMS with MDM2 overexpression showed a worse prognosis than DDLS (P = 0.0408). No significant difference in prognosis was found between LMS without MDM2 overexpression and DDLS with myogenic differentiation. In conclusion, we recommend that systemic MDM2 expression analysis be performed in cases of retroperitoneal sarcoma. Overdependence on the expression of myogenic markers could lead to misdiagnosis in distinguishing LMS from DDLS.

AB - It is important to distinguish between leiomyosarcoma (LMS) and dedifferentiated liposarcoma (DDLS) in the retroperitoneum. The dedifferentiated component of DDLS shows an LMS-like morphology in some cases; thus, detailed evaluation is necessary to achieve an accurate diagnosis. Immunohistochemically, MDM2 and myogenic markers provide clues for the diagnoses. However, immunoreactivity for MDM2 and myogenic markers has not been well studied in retroperitoneal LMS and DDLS. Here, we compared the clinicopathological data of 20 retroperitoneal tumors initially diagnosed as LMS with that of 36 cases of retroperitoneal DDLS and conducted an immunohistochemical study. Four (20%) of the cases initially diagnosed as LMS were immunoreactive for MDM2. Fifteen cases (41.7%) of DDLS showed positive expression of two or more myogenic markers. The patients with LMS with MDM2 overexpression were older than the patients with LMS without MDM2 overexpression (P = 0.0328). LMS with MDM2 overexpression showed a worse prognosis than DDLS (P = 0.0408). No significant difference in prognosis was found between LMS without MDM2 overexpression and DDLS with myogenic differentiation. In conclusion, we recommend that systemic MDM2 expression analysis be performed in cases of retroperitoneal sarcoma. Overdependence on the expression of myogenic markers could lead to misdiagnosis in distinguishing LMS from DDLS.

UR - http://www.scopus.com/inward/record.url?scp=85019636110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019636110&partnerID=8YFLogxK

U2 - 10.1016/j.prp.2017.04.022

DO - 10.1016/j.prp.2017.04.022

M3 - Article

VL - 213

SP - 634

EP - 638

JO - Pathology Research and Practice

JF - Pathology Research and Practice

SN - 0344-0338

IS - 6

ER -